Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05579093 · ClinicalTrials.gov registry record
Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia
A clinical trial, sponsored by Columbia University.
- Completed
- Registry status
- 325
- Enrollment target
NCT05579093: Completed study, sponsored by Columbia University.
NCT05579093 is a clinical trial that has completed, run by Columbia University. The registered enrollment target is 325 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05579093 has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 325 participants
- Enrollment target
Study Summary
Neurotrack™ is an FDA-approved device for measuring and tracking cognitive decline, as may occur with age-related cognitive decline and Alzheimer's disease. The device uses a webcam (World Wide Web enabled camera) to assess eye-tracking as the subject views black-and-white images on the computer screen. The test takes less than 5 minutes to complete. This study will examine the feasibility and utility of pre-operative assessment of cognition using Neurotrack™ technology. The predictive value of Neurotrack™ will be compared to our previous work using pupillometry. The primary outcome is a measure of delirium in the recovery room and secondary outcomes include total length of stay, intensive care unit (ICU) length of stay, and readmissions within 30 days of surgery.
Primary Outcome
Prevalence of delirium in in the post anesthesia care unit (PACU) will be calculated.
Interventions
- COMBINATION_PRODUCT Cognitive test + Pupillary measure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2021-09-20 |
What the finished NCT05579093 record still lists
NCT05579093 is an observational study that tracks outcomes without assigning an intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Cognitive test + Pupillary measure is the first listed.
NCT05579093 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05579093 about?
NCT05579093 is a clinical study titled "Clinical Investigation of an Eye-Tracking Device as a Predictor of Delirium in the Recovery Room After Surgery With General Anesthesia". Neurotrack™ is an FDA-approved device for measuring and tracking cognitive decline, as may occur with age-related cognitive decline and Alzheimer's disease. The device uses a webcam (World Wide Web enabled camera) to assess eye-tracking as the subject views black-and-white images on the computer scr...
What is the current status of trial NCT05579093?
This trial is currently completed. The enrollment target is 325 participants. The study started on 2019-10-01. Estimated completion is 2021-09-20.
What interventions are being tested in trial NCT05579093?
The interventions under investigation include: Cognitive test + Pupillary measure (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05579093?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI